Liposomal Clodronate as a Therapy for Autoimmune Hemolytic Anemia

Tech ID: 02-07

NOTE: THIS TECHNOLOGY IS EXPERIMENTAL AND THEREFORE IT IS NOT AVAILABLE TO HUMANS. IT HAS ONLY BEEN TESTED IN MICE AND DOGS DIAGNOSED WITH AIHA

Summary - This invention is using liposomal clodronate as a therapy for autoimmune hemolytic anemia (AIHA).

Potential Applications

  • Therapy for autoimmune hemolytic anemia
  • The therapy is applicable to both humans and companion animals

Advantages of Invention

  • The method is less invasive than surgery (splenectomy)
  • Decrease use of steroids
  • Decrease side effects

State of Development

  • The efficacy of this therapy has been demonstrated by some strong in vivo data obtained in mice and dogs with AIHA.
  • Using a mouse model in which animals were given anti red blood cell antibodies, treatment with liposomal clodronate substantially decreased red blood cell destruction.
  • In addition, this effect was detected within hours and lasted at least a week.

Further R&D Required - Additional in vivo studies with other animal models.

Licensing Potential - Available for licensing.

Inventors - Mike Jordan, MD, Philippa Marrack, PhD and John Kappler, PhD

Publications


Patent Status - U.S. Patent #7,090,865

 

02-07a RBC clearance and the effects of LC treatment in dogs with AIHA. RBC clearance in 6 dogs with spontaneous AIHA was assessed by flow cytometry prior to treatment and again 24 hours after treatment with LC and the mean (± SE) percentage of labeled RBC present in circulation at each time point post infusion was determined. (B) RBC clearance kinetics were determined again 24 hours after treatment with 0.5 mL/kg LC. In 4 dogs (Nonresponders), there was no change in RBC clearance compared to clearance prior to treatment with LC, whereas in 2 dogs (Responders), RBC clearance was markedly reduced.

 

 

For Further Information, Contact:
Emmanuel Hilaire, PhD
Manager
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: (303) 398-1262
Fax: (303) 270-2352
HilaireE@njhealth.org

Featured Research 

Severe Allergic Reactions and the EpiPen
New research indicates that young children suffer allergic reactions to food more frequently than doctors realized, and that more caregivers need know how to use an EpiPen.

Faculty by Research

The discoveries made in the laboratories at National Jewish Health have a profound impact on the understanding and treatment of human disease.

Browse our Faculty by Area of Research.